Biotech China 2014

Profile Details
William Stohl
Affiliations:

Keck School of Medicine of USC



 
, US
Phone:
Fax:
My Blogs:
 
Age:
Bio:
 
Specialty:
Rheumatology
 
Presented at Events Covering:
Autoimmunity, Biology, Cancer Biology, Cell Biology, Cytokine, Epidemiology, Immunobiology, Immunology, Microbiology, Neuroscience, Psychiatry, Pulmonary Disease, Rheumatology, Surgery
 
Areas of Interest:
 
Hobbies:
 
General Comments:
BSN Rank: 96 / 2961 (What's this?)
Accomplish Score: 2276
Popularity Score: Unavailable
# in My Circle: 0
# in My Org(s): 1
We'll Post Your CV for Free!
 
 
Speaking/Presenting-Abstract/Poster at Mtg: 68 (884 / 0)
 
Honors and Awards: 0 (0 / 0)
 
Clinical Trial Activity: 0 (0 / 0)
 
Grant Support: 48 (432 / 0)
  • A long-term, open-label follow-up study of tasocitinib (CP-690,550) for treatment of rheumatoid arthritis (A3921024). (2011 - Present)
  • A phase II, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of MLTA3698A in combination with a disease-modifying anti-rheumatic drug (DMARD) compared with adalimumab in combination with a DMARD in patients with active rheumatoid arthritis (2011 - Present)
  • A multi-center, continuation trial of belimumab (HGS 1006, LymphoStat-BTM), a fully human monoclonal anti-BLyS antibody, in subjects with systemic lupus erythematosus (SLE) who completed the phase 3 protocol HGS1006-C1056 in the United States (2010 - Present)
 
Patents Pending: 0 (0 / 0)
 
Journal - Editor/Reviewer: 35 (245 / 0)
  • International Journal of Clinical Rheumatology (2010 - Present)
  • Future Rheumatology (2007 - Present)
  • Expert Opinion on Therapeutic Targets (2005 - Present)
 
Peer Reviewed Papers, Books, Chapters: 104 (624 / 0)
  • Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase 2, randomized, double-blind, placebo-controlled, dose-ranging study (2013)
  • Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor (2013)
  • Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development? (2012)
 
Pre/Non Reviewed Papers, Proceedings: 0 (0 / 0)
 
Membership in Professional Societies: 30 (90 / 0)
  • Advisory Committee for The Center for Human Studies, USC Clinical and Translational Science Institute (2007 - Present)
  • USC Division of Rheumatology (2007 - Present)
  • USC Division of Rheumatology Journal Club (2005 - Present)
 
White Papers: 0 (0 / 0)
 
Registered on BiotechScienceNews: 1

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.